IntelGenx Technologies (IGXT)
(Delayed Data from OTC)
$0.16 USD
0.00 (-0.67%)
Updated Apr 23, 2024 03:57 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
IntelGenx Technologies Corp. [IGXT]
Reports for Purchase
Showing records 1 - 20 ( 32 total )
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Rizaport Hit With Another Delay; Lower $0.50PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Rizaport PDUFA in 1Q20; Multiple Pipeline Programs Progressing Well; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Rizaport and Tadalafil Programs in Focus; Adjusting PT to $1.00; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Rizaport NDA Resubmission by 3Q19; Collaboration Agreement With Aquestive; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Rizaport PDUFA Date on April 1 Could Be a Big Catalyst; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Moving Closer to Rizaport Launch; Entering the Red- Hot Cannabis Market with Tilray; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Tadalafil Film on Track for 4Q18 Launch; Alzheimer''s Study Results in 2019; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Two Potential U.S. Approvals by YE18; Lower $1.50 PT on Dilution; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Expect Two Major Approvals in 2019; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
NDA Delay Likely Temporary; Rizaport Rights Returned to IntelGenx; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Rizaport PDUFA Date in 1H18; Tadalafil on Track to File by Year End; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Rizaport NDA Resubmitted; On Track for U.S. Approval in 1H18
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Two NDAs to File in 2H17; Montelukast Phase 2 to Start in 4Q17; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Two NDAs Filings in Mid-2017; Montelukast Advancing Into Phase 2; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Tadalafil on Track for Mid-2017 Filing; Manufacturing Expansion Planned; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
An Opportunistic Agreement With Tetra Bio- Pharma; Focus Remains on Films; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Lilly Agreement Clears the Legal Path for Tadalafil VersaFilm; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IntelGenx Technologies Corp.
Industry: Medical - Drugs
Rizaport Heading Back to the FDA; Montelukast Moves to Phase 2; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S